The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver Microsomes
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 2×
“The level of this enzyme was undetectable in 70% of Japanese and in 15% of Caucasians as recently reported (Shimada et al., 1994).”
MethodResultKetamine—its pharmacology and therapeutic uses
white, P. F., Way, W. L., & Trevor, A. J. (1982) · Anesthesiology · doi:10.1097/00000542-198202000-00007 · Cited by 1,474
Lang, T., Klein, K., Fischer, J., Nussler, A. K., Neuhaus, P., Hofmann, U., Eichelbaum, M., Schwab, M. G., & Zanger, U. M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00004 · Cited by 571
Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
Iwatsubo, T., Hirota, N., Ooie, T., Suzuki, H., Shimada, N., Chiba, K., Ishizaki, T., Green, C. E., Tyson, C. A., & Sugiyama, Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00184-2 · Cited by 479
Bourrié, M., Meunier, V, Berger, Y., & Fabre, G. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12826-7 · Cited by 363
Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9
Baldwin, S. J., Bloomer, J. C., Smith, G. J., Ayrton, A. D., Clarke, S. E., & Chenery, R. J. (1995) · Xenobiotica · doi:10.3109/00498259509061850 · Cited by 298
Guengerich, F. P., & Turvy, C. G. (1990) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23168-8 · Cited by 266
Code, E. L., Crespi, C. L., Penman, B. W., Gonzalez, F. J., Chang, T. K. H., & Waxman, D. J. (1997) · PubMed · Cited by 245
Selective Inhibitors of Cytochromes P450
Halpert, J. R., Guengerich, F. P., Bend, J. R., & Correia, M. A. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1061 · Cited by 214
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms.
Ko, J. W., Sukhova, N., Thacker, D. L., Chen, P., & Flockhart, D. A. (1997) · PubMed · Cited by 209
Cited by
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 569
Toxicity of amphetamines: an update
Carvalho, M., Carmo, H., Costa, V. M., Capela, J. P., Pontes, H., Remião, F., Carvalho, F., & Bastos, M. D. L. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0815-5 · Cited by 431
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282
Rehmel, J. L. F., Eckstein, J. A., Farid, N. A., Heim, J. B., Kasper, S. C., Kurihara, A., Wrighton, S. A., & Ring, B. J. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.007989 · Cited by 261
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Irwin, S. A., Iglewicz, A., Nelesen, R. A., Lo, J. Y., Carr, C. H., Romero, S. D., & Lloyd, L. S. (2013) · Journal of Palliative Medicine · doi:10.1089/jpm.2012.0617 · Cited by 167
Stereoselective and regiospecific hydroxylation of ketamine and norketamine
Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.685777 · Cited by 114
“This transformation has been extensively studied (Trevor et al. 1983; Kharasch & Labroo 1992; Hijazi & Boulieu 2002; Portmann et al. 2010) and is enantioselective hydroxylation of ketamine [(R,S)-Ket] to diastereomeric hydroxyketamines, (2S,6S;2R,6R)-HK (5a) and (2S,6R;2R,6S)-HK (5b) and…”
Arabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.02.056 · Cited by 89
The profile of cognitive impairments in chronic ketamine users
Ke, X., Ding, Y., Xu, K., He, H., Wang, D., Deng, X., Zhang, X., Zhou, Y., Zhou, C., Liu, Y., et al. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.05.050 · Cited by 67
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Metadata
- Authors
- Hijazi, Y., & Boulieu, R.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2002-07
- Volume
- 30
- Issue
- 7
- Pages
- 853-858
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2013294274
- Cited by
- 287
- References
- 29
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.